Novo Nordisk A/S
(OMX Nordic Exchange Copenhagen A/S : NONOF)

( )
NONOF PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
0.23%128.000.7%$1097.34m
PFEPfizer Inc.
-0.03%36.450.9%$576.34m
ABBVAbbVie, Inc.
1.13%77.322.3%$573.89m
MRKMerck & Co., Inc.
-0.18%84.530.7%$568.93m
BMYBristol-Myers Squibb Co.
0.34%53.211.4%$527.64m
LLYEli Lilly & Co.
-0.65%107.931.1%$271.99m
NVSNovartis AG
-0.40%86.540.2%$148.78m
RETAReata Pharmaceuticals, Inc.
-1.59%181.973.8%$131.98m
AZNAstraZeneca Plc
-0.37%43.711.2%$125.96m
RARXRa Pharmaceuticals, Inc.
0.02%46.250.8%$98.49m
GSKGlaxoSmithKline Plc
0.17%42.600.2%$95.87m
SNYSanofi
-0.50%45.940.2%$71.86m
NVONovo Nordisk A/S
0.19%52.620.1%$62.64m
DOVADova Pharmaceuticals, Inc.
0.89%28.320.0%$32.53m
TAKTakeda Pharmaceutical Co., Ltd.
0.98%17.520.0%$27.86m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.